Severe anaphylaxis caused by orally administered vancomycin to a patient with clostridium difficile infection

Infection

Volumn 41, Issue 2, 2013, Pages 579-582

  Bosse D ^a   Lemire, C ^a   Ruel, J ^a   Cantin, A M ^a   Menard F ^a   Valiquette, L ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Anaphylaxis; Clostridium difficile; Oral vancomycin; Tigecycline

Indexed keywords

ADRENALIN; DIPHENHYDRAMINE; IMMUNOGLOBULIN; LINEZOLID; METHYLPREDNISOLONE; METRONIDAZOLE; RANITIDINE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; ADULT; ANAPHYLAXIS; ARTICLE; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; CYSTIC FIBROSIS; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FACE EDEMA; HUMAN; LOADING DRUG DOSE; LUNG INFECTION; MALE; RECURRENT INFECTION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANAPHYLAXIS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CYSTIC FIBROSIS; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; MALE; METRONIDAZOLE; MINOCYCLINE; SEVERITY OF ILLNESS INDEX; VANCOMYCIN;

EID: 84879500036     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0328-4     Document Type: Article

References (26)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-55.
2. Bauer MP, Kuijper EJ, van Dissel JT; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15:1067-79.
3. Gonzales M, Pepin J, Frost EH, et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis. 2010;10:363.
4. Osawa R, Kaka AS. Maculopapular rash induced by oral vancomycin. Clin Infect Dis. 2008;47:860-1.
5. Bailey P, Gray H. An elderly woman with 'Red Man Syndrome' in association with oral vancomycin therapy: a case report. Cases J. 2008;1:111.
6. Bergeron L, Boucher FD. Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function. Ann Pharmacother. 1994;28:581-4.
7. Renz CL, Laroche D, Thurn JD, et al. Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions. Anesthesiology. 1998;89:620-5.
8. Ebo DG, Verheecke G, Bridts CH, Mertens CH, Stevens WJ. Perioperative anaphylaxis from locally applied rifamycin SV and latex. Br J Anaesth. 2006;96:738-41.
9. Greenberg K, Espinosa J, Scali V. Anaphylaxis to topical bacitracin ointment. Am J Emerg Med. 2007;25:95-6.
10. Saryan JA, Dammin TC, Bouras AE. Anaphylaxis to topical bacitracin zinc ointment. Am J Emerg Med. 1998;16:512-3.
11. Scala E, Giani M, Pirrotta L, Guerra EC, De Pità O, Puddu P. Multiple drug allergy syndrome: severe anaphylactic reaction due to topical rifamycin SV in a patient with hypersensitivity to ciprofloxacin. Int J Dermatol. 2001;40:603-4.
12. Taylor SL, Hefle SL, Bindslev-Jensen C, et al. Factors affecting the determination of threshold doses for allergenic foods: how much is too much? J Allergy Clin Immunol. 2002;109:24-30.
13. Crespo JF, Pascual C, Dominguez C, Ojeda I, Muñoz FM, Esteban MM. Allergic reactions associated with airborne fish particles in IgE-mediated fish hypersensitive patients. Allergy. 1995;50:257-61.
14. Ramesh S. Antibiotic hypersensitivity in patients with CF. Clin Rev Allergy Immunol. 2002;23:123-41.
15. Pham NH, Baldo BA, Puy RM. Studies on the mechanism of multiple drug allergies. Structural basis of drug recognition. J Immunoassy Immunochem. 2001;22:47-73.
16. Cheong EY, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis. Med J Aust. 2011;194:374-5.
17. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis. 2009;48:1732-5.
18. Lu CL, Liu CY, Liao CH, Huang YT, Wang HP, Hsueh PR. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents. 2010;35:311-2.
19. El-Herte RI, Baban TA, Kanj SS. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. Scand J Infect Dis. 2012;44:228-30.
20. Kopterides P, Papageorgiou C, Antoniadou A, et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care. 2010;38:755-8.
21. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012; 55 Suppl 2:S154-61.
22. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin re-expression and recurrence of CDI. Clin Infect Dis. 2012; 55 Suppl 2:S132-42.
23. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother. 2009;53(1):261-3.
24. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012;55 Suppl 2:S121-6.
25. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother. 2008;52(7):2403-6.
26. Liss BJ, Vehreschild JJ, Cornely OA, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012. doi: 10.1007/s15010-012-0269-y